Physical function in men with prostate cancer on androgen deprivation therapy.

Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer death in men. (1) Androgen deprivation therapy (ADT) has become an increasingly standard intervention for both early and advanced stages of prostate cancer. (2,3) Studies have shown that ADT is similar to orchiectomy in its ability to suppress plasma levels of testosterone, and both interventions share the adverse effects of hot flashes and loss of libido. (4)

Stoch et al (5) and Maillefert et al (6) have previously demonstrated that men on ADT have poor skeletal integrity, as shown by low bone mineral density and high levels of biochemical markers of bone turnover. These men also have a higher percentage of total body fat and a lower percentage of lean body mass compared with men who are eugonadal. (5) Androgen deprivation therapy is known to affect quality of life adversely, leading to increased fatigue, erectile difficulties, and decline in sexual function. (3,7,8) Dacal et al (9) demonstrated that men on short- and long-term ADT have poorer quality of life in the dimensions of physical function and general health, as reflected by a lower physical health component summary score from a questionnaire. Physical function and gait, however, were not measured. This is clinically relevant because poor gait speed has been associated with greater disability and risk of major health-related outcomes in community-dwelling populations. (10,11)

Although decreased physical function has been reported in men receiving ADT, (12,13) limited studies have measured physical performance. (3,14) Because of the hypogonadism induced by the ADT (15) and the association of testosterone with muscle strength (force-generating capacity), our objective was to determine whether ADT (and hypogonadism) resulted in decreased strength and mobility. Furthermore, because lower testosterone levels have been associated with impairment in cognitive function, we examined the effect of ADT on an associated test of cognitive and motor function by assessing visuomotor performance. These findings could provide the rationale for health care providers to help maintain or improve physical and visuomotor function.

We postulated that men who were hypogonadal because of ADT would be more likely to have deficits in physical function and visuomotor performance than men who were eugonadal. We also postulated that a longer duration of ADT would be associated with a greater reduction in function.

Materials and Method

Subjects

Men with prostate cancer and control subjects who were healthy were recruited from the private practices of the University of Pittsburgh physicians, local newspaper advertisements, and cancer support groups as described previously. (9,16) All participants were community-dwelling men 50 years of age and older. We enrolled men with prostate cancer, but without evidence of metastatic disease, who were or were not treated with ADT, in addition to a group of men of similar ages but without prostate cancer. The participants were part of a longitudinal study to examine the effect of ADT on skeletal health. (16)

Men were excluded if they had any disease or were taking any medication known to affect bone and mineral metabolism. We included men willing to participate in this substudy to examine physical function. Additional exclusion criteria based on musculoskeletal impairments were not included; however, control subjects who were hypogonadal were excluded. Androgen deprivation therapy was defined as orchiectomy, gonadotrophin-releasing hormone agonists, anti-androgens, or a combination of these interventions. Participants were categorized into 4 groups: (1) men with prostate cancer who were not taking ADT (no ADT), (2) men with prostate cancer who were on short-term ADT (<6 months) (short-term ADT), (3) men with prostate cancer who were on long-term ADT ([greater than or equal to] 6 months) (long-term ADT), or (4) older men without prostate cancer (control subjects)

All patient visits were performed at the General Clinical Research Center, Montefiore University Hospital, University of Pittsburgh, Pittsburgh, Pa. All tests were completed at one visit, with the exception of body composition measurements; 10% of participants had this performed within 1 month of the other tests. Although the study coordinator was aware of subject group assignment, the investigator who assessed physical function was not. Written informed consent was obtained from all subjects prior to their enrollment.

Outcome Measures

Measures of body composition. Measures of body composition included height (in centimeters), weight (in kilograms), and body mass index (BMI) (in kilograms per square meter). Height was measured to the nearest centimeter using a Harpenden stadiometer, * and weight was measured with a standard balance beam scale. Percentage of body fat and lean body mass were measured with dual-energy X-ray absorptiometry (DXA) using a QDR-4500A bone densitometer. (17),([dagger]) Assessment of body composition by DXA is based on the attenuation of the alternation of an x-ray beam, from a source with 2 energies, passing through the body. The attenuation ratio of these 2 energies is used to distinguish soft tissue from bone and to distinguish fat soft tissue from lean soft tissue.18 This method accurately predicts skeletal muscle assessed by magnetic resonance imaging. (19)

Testosterone and prostate-specific antigen (PSA) levels. Total testosterone was measured by competitive immunoassay (Bayer Centaur ([double dagger])) (in nanograms per deciliter; normal range=260-1,000 ng/ dL; intra-assay coefficient of variation [CV]=2.4%-8.3%). Free testosterone was measured by tracer equilibrium dialysis ([double dagger]) (in picograms per milliliter; normal range=50-210 pg/ mL; intra-assay CV=4.2%-11.6%). Prostate-specific antigen was measured by competitive immunoassay (in nanograms per milliliter; normal range=0-4 ng/mL; intra-assay CV=4.0%-4.4%).

Comorbidity Disease Index (CMDI). The CMDI is a patient self-report that includes 18 common conditions that affect performance on physical function tasks. (20) Scores range from 18 to 36, with a score of 18 representing having all conditions and a score of 36 representing having no conditions. The 18 medical conditions correspond to 8 domains: cardiac, respiratory, diabetic, neurological, cancer, vision, musculoskeletal, and generalized medical conditions (eg, depression, emotional problems, sleep problems, chronic pain). The agreement between self-reported disease and chart diagnosis ranged from 84% to 94% (kappa statistic= .56-.67). (20)

Digit Symbol Substitution Test (DSST). The DSST from the Wechsler Adult Intelligence Scale-Revised (21) was administered to all participants. The DSST measures visuomotor performance; it requires response speed, sustained attention, visual spatial skills, and set shifting. We presented the participants with a coding key pairing 9 numbers (1-9) with 9 symbols. Participants were first given a practice sample of 10 items. Then, they were given 90 seconds to transcribe as many symbols as possible into the empty boxes, based on the digit-symbol associations specified in the coding key.

Nine-Hole Peg Test (9HP). The 9HP is a quantitative measure of upper-extremity (arm and hand) function. (22) Participants were given a 9-hole pegboard and a dish of 9 pegs. Each individual was asked to remove all 9 pegs from the dish, place them in the holes, and then return them to the dish with one hand. The test began with a practice run and then continued with a timed measure of the dominant hand and the nondominant hand in the order the participant preferred.

Short Physical Performance Battery (SPPB). The SPPB was based on the Established Population for Epidemiologic Studies of the Elderly (EPESE) lower-extremity performance battery. (23) Lower-extremity function was assessed by measures of standing balance, gait speed, and ability to rise from a chair. A 5-level categorical score was created for each test, with 0 representing inability to complete the test and 4 representing the highest level of performance. (23)

For tests of standing balance, participants attempted to maintain the side-by-side, semi-tandem, and tandem positions for 10 seconds. The participants then were asked to walk a 4-m length at their usual pace from a standing start. The time of the faster of 2 walks was used for scoring. Finally, participants were asked to fold their arms across their chest and to stand up from a sitting position once. If they successfully rose from the chair, they were asked to stand up and sit down 5 times as quickly as possible. Participants were instructed to come to a full standing position and sit so their backs were touching the back of the chair. A summary performance score was created by summation of the scores for each test (score range= 0-12).

Data Analysis

All data analyses were performed using SAS software, version 9.1. ([section]) Descriptive statistics were used to characterize the 3 groups of subjects with prostate cancer in the study sample. Analysis of variance was used to compare characteristics among the 4 groups (including the control group). Correlations between various subject characteristics and physical and visuomotor function were examined using Pearson correlation coefficients. General linear models were used to make: (1) unadjusted comparisons of physical function across the 4 groups and (2) adjusted comparisons across the 4 groups controlling for covariates identified as being important in the bivariate correlation analyses. Graphical analysis of residuals from regression models was performed to identify any violations of the standard distributional assumptions.

Results

Clinical Characteristics

Of the 152 participants in the original longitudinal study, (16) 102 men agreed to participate in this study. Two control subjects were found to be hypogonadal and were excluded from the analyses. The final cohort of 100 men included 25 men with prostate cancer who were not treated with ADT, 13 men with prostate cancer who were on short-term ADT, 42 men with prostate cancer who were on long-term ADT, and 20 men without prostate cancer (Tab. 1). Men who were on long-term ADT were receiving treatment for an average ([+ or -] SD) of 31 [+ or -] 29 months.

There were significant differences in age across the 4 groups; men who were on short-term or long-term ADT were older than men who were not on ADT or the control subjects. There were no significant between-group differences in BMI. However, men who were receiving long-term ADT had the highest total body fat and lowest lean body mass compared with the other 3 groups (P<.01, Tab. 1). As expected, levels of total and free testosterone were significantly lower in men who were receiving ADT than in those who were not on ADT or the control subjects (Tab. 1). Prostate-specific antigen levels were higher in men who were on short-term ADT compared with men who were on long-term ADT. The overall CMDI score was lower in the men with prostate cancer compared with the control subjects. The prevalence of comorbid conditions (Tab. 1) for the cohort was similar among groups for cardiovascular disease (5%-24%), pulmonary disease (12%-17%), musculoskeletal disease (50%-74%), diabetes mellitus (0%-7%), vision problems (16%-40%), neurological disease (20%-31%), and generalized symptoms (eg, depression, sleep problems, chronic pain) (0%-15%).

Functional Performance

The control subjects, on average, walked at 1.17 m/s, whereas men who were on long-term ADT walked at 0.99 m/s (P<.001) (Tab. 2). This difference persisted after controlling for subject characteristics found to be important in the bivariate correlation analyses. After adjusting for age, CMDI, and percentage of body fat, men who were on long-term ADT walked 0.18 m/s slower than men who did not have prostate cancer (P<.001). Among men with cancer, there was no significant difference in gait speed between those who were on short- or long-term ADT and those who were not on ADT (P=.44 and P=.38, respectively) after adjusting for the covariates.

Scores on the SPPB were significantly different across the 4 groups after adjusting for the same covariates (P=.02). Men with prostate cancer who were not on ADT or who were on short-term ADT had SPPB scores 0.8 and 1.1 points greater than men who were on long-term ADT (P=.04 and P=.01, respectively) (Tab. 2). Visuomotor performance assessed by the DSST was significantly different across the 4 groups (P=.02). Other measures of physical function were similar across the 4 groups (Tab. 2).

Associations Between Predictor Variables and Function

Although statistically significant, there were only marginal to moderate associations between subject characteristics and function (Tab. 3). The greatest unadjusted associations were between CMDI and DSST (r=.36, P<.001), CMDI and speed on the 9HP with the nondominant hand (r=-.23, P=.02), age and walking speed (r=.23, P=.02), CMDI and time to rise from a chair (r=-.20, P=.05), and CMDI and SPPB (r=.26, P<.01).

Discussion

In our study of mobility and physical function in older men with and without prostate cancer, we observed that gait speed varied across the 4 groups and that men who were on long-term ADT had a significantly slower gait speed than the control subjects (Figure). Function, as measured by the SPPB, also varied significantly across the groups, with men who were not on ADT or men who were on short-term ADT performing significantly better than men who were on long-term ADT. Finally, although visuomotor performance varied across the 4 groups, it was not significantly lower in any single group, suggesting that ADT had a minimal effect on this parameter.

Several investigators have examined mobility in men with prostate cancer who were on ADT. July and colleagues (14) examined physical function using a limited walk test, grip strength, and the Timed "Up & Go" Test in men who were on ADT versus control subjects and reported no significant differences. In the present study, we assessed gait speed using the 4-m walk test and found that men with prostate cancer who were on long-term ADT had slower gait speed than the control subjects. Potential reasons for differences in the findings include a different test of gait (a 6-minute walk test by Joly and colleagues compared with a 4-m walk test in the present study) and differences in the duration of ADT (up to 7.4 years in the study by July et al and up to 11 years in our study).

Perera et al (24) previously showed that small meaningful differences in gait speed are near 0.05 m/s, which was observed between our patient groups. Furthermore, in a population of more than 3,000 older people who were well functioning, Cesari and colleagues (11) reported that a gait speed of less than 1 m/s identifies people who are at higher risk for health-related outcomes. Data from the 1999-2002 National Health and Nutrition Examination Survey also showed that walking speed was inversely related to disability. (25) Other investigators (10) have developed models using gait speed that predict disability in elderly people. Therefore, clinicians should monitor for a decrease in gait speed or mobility in men with prostate cancer who are on long-term ADT.

Forrest et al (26) demonstrated that gait speed decreases with age. We also observed that gait speed decreased with age in our cohort. Furthermore, in elderly people, a higher fat mass or lower lean body mass has been associated with a slower walking speed and greater likelihood of functional limitation. (27) We did not find a relationship between gait speed and body composition, either fat or lean mass. The difference between our study and the report by Sternfeld et al (27) may be due to methods used for determining gait speed (4-m walk versus distance walked in 60 seconds). However, a more likely reason for the difference in associations between body composition and gait speed in the 2 studies may be the degree of debilitation of the subjects. In the study by Sternfeld et al, (27) the average group gait speed was 0.69 m/s, whereas gait speed averaged between 0.99 and 1.17 m/s in our study. The slower gait speed may indicate more debilitation and perhaps greater changes in body composition and lean muscle mass.

In the present study, we observed small meaningful differences (24) in SPPB scores of 0.8 point between men with prostate cancer who were on long-term ADT and men with prostate cancer who were not on ADT and 1.1 points between men who were on short-term ADT and men who were on long-term ADT (both P<.05). In a study that examined upper-extremity strength by handgrip, Stone and colleagues (28) found no difference in strength after 3 months of ADT. In a cross-sectional study by Basaria et al, (29) however, men on ADT for a mean of 45 months had reduced upper-body strength (by bench press) but not lower-body strength (by leg press) compared with control subjects. Because we did not assess strength by these measures, it is difficult to know whether the differences in the SPPB scores were due to decreased muscle strength or other factors.

Men who were on long-term ADT had approximately 4.5% less lean body mass than the control subjects, men who were not on ADT, or men who were on short-term ADT. Stoch and colleagues (5) described a higher percentage of body fat and lower lean body mass in men with prostate cancer who were on ADT versus men with prostate cancer who were not receiving ADT. Greenspan et al (16) recently reported a loss of muscle mass and bone with an increase in body fat in men receiving short-term ADT who were followed over 12 months. Because the current cross-sectional study included men in the short-term group with a mean duration of ADT of 3.7 months, this may not have been a long enough duration to see a difference in lean body mass. Smith and colleagues (30) also discovered an association between decreased muscle size and ADT, which may have contributed to frailty and increased risk of falls in the men in their study.

[FIGURE OMITTED]

We expected men who were hypogonadal, with low levels of testosterone, to have deficits in measures of physical function. Although testosterone levels were lower in men on ADT, total and free testosterone levels were not associated with scores on the SPPB measure of physical function in the present study. Serum testosterone levels decline gradually and progressively with aging in men. Many manifestations associated with aging, including muscle atrophy and weakness, increased fat body mass, and decreased lean body mass, are similar to changes associated with testosterone deficiency in young men. (31) It is controversial whether giving testosterone to older men who are hypogonadal improves muscle strength, body composition, or even cognitive function. (32-34)

Several investigators have examined the effect of exercise in men with prostate cancer who were on ADT. Segal et al (35) reported that resistance training reduced fatigue and improved muscular fitness in men with prostate cancer who were on ADT. Galvao et al (36) reported that a 20-week program of progressive resistance training improved muscle strength, functional performance, and balance in older men who were on ADT. Exercise also may improve gait speed in older adults. (37) Therefore, clinicians may consider physical therapy intervention for strength and gait interventions in these patients.

Little is known about the effect of ADT on visuomotor performance. There have been suggestions that lowered testosterone levels in older men who are healthy are associated with impairment of cognitive function (38) and that testosterone replacement therapy may improve some cognitive domains, specifically visuospatial and working-memory function. (32) The present study showed that visuomotor performance, as measured by DSST, varied across the groups but was not significantly lower in any one group.

Salminen et al (39) demonstrated that men who were on ADT for 12 months had preserved cognitive function, as assessed by a battery of cognitive performance tests that included verbal visuomotor and memory tests. Similarly, Green et al (12) found that, after 6 months of ADT, one half (n=50) of men receiving treatment had a clinically significant decrease on at least one cognitive task; however, no change was noted on DSST performance. Data from all of these studies suggest that ADT in men with prostate cancer may not have a significant effect on visuomotor performance. Future studies may need to do more sophisticated testing to find subtle declines in cognitive performance.

There are several limitations of this study. First, the men with prostate cancer who were not on ADT and the control subjects were younger than the men who were on ADT. However, when we adjusted for age, the between-group differences prevailed. Second, this is a relatively small, cross-sectional, secondary analysis of an observational study, which may have limited the statistical power and does not allow us to draw conclusions about the longitudinal patterns of cause and effect. Third, maximum participant effort for each task may not have been optimal, although participants were routinely given a practice run for these assessments.

This study also had several strengths. First, all men were seen at the same facility with the same coordinators administering the tests, reducing variability from nuisance factors. Second, a control group of older men without prostate cancer was included. Third, in addition to ADT, testosterone levels were assessed to determine whether the therapy or the hypogonadal state had the most significant effect. Finally, comorbidity was adjusted for, which has not been done in many studies.

Conclusion

The men with prostate cancer who were on long-term ADT (for more than 6 months) had a reduced gait speed compared with control subjects. Physical performance was decreased in men who were on long-term ADT compared with men who were not on ADT or who were on short-term ADT. Androgen deprivation therapy did not have a significant effect on visuomotor function. Because a reduced gait speed and a decrease in physical function are critical components for activities of daily living, this finding warrants further investigation. These findings have important clinical ramifications and suggest that long-term ADT can contribute to a decline in mobility and function in older men with prostate cancer.

Dr Clay and Dr Greenspan provided concept/idea/research design and project management. Dr Clay, Dr Perera, and Dr Greenspan provided writing. Dr Clay, Ms Wagner, and Ms Miller provided data collection. Dr Clay, Dr Perera, and Dr Greenspan provided data analysis. Dr Greenspan provided fund procurement and facilities/equipment. Dr Nelson provided subjects. Ms Miller provided clerical/secretarial support. Dr Perera and Dr Nelson provided consultation (including review of manuscript before submission).

The study protocol was approved by the Institutional Review Board of the University of Pittsburgh.

The project was supported by a Mentored Medical Student in Clinical Research Fellowship Award through the General Clinical Research Center at the University of Pittsburgh to Dr Clay; a K24 Patient-Oriented Mid-Career Award from the National Institutes of Health/National institute of Diabetes and Digestive and Kidney Diseases (K24 DK062895) to Dr Greenspan; a grant to the General Clinical Research Center, University of Pittsburgh, from the National institutes of Health/National Center for Research Resources (MO1 RR000056); and a grant to the Claude D Pepper Older Americans Independence Center, University of Pittsburgh, from the National Institutes of Health/National Institute on Aging (P30 AG024827). None of the funding sources played a role in the design or execution of the study, the analysis and interpretation of data, or the writing of the manuscript.

This article was submitted October 3, 2006, and was accepted May 23, 2007.

DOI: 10.2522/ptj.20060302

References

(1) Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.

(2) Demers RY, Tiwari A, Wei J, et al. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001;92:2309-2317.

(3) Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60: 201-215.

(4) Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154-179.

(5) Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787-2791.

(6) Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219-1222.

(7) Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:3750-3757.

(8) Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, et al. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer. 2002;95:287-295.

(9) Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006;54:85-90.

(10) Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221-M231.

(11) Cesari M, Kritchevsky SB, Penninx BW, et al. Prognostic value of usual gait speed in well-functioning older people: results from the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2005; 53:1675-1680.

(12) Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90: 427-432.

(13) Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93:975-979.

(14) Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6 pt 1): 2443-2447.

(15) Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980;93:109-114.

(16) Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90:6410-6417.

(17) Prior BM, Cureton KJ, Modlesky CM, et al. In vivo validation of whole body composition estimates from dual-energy x-ray absorptiometry. J Appl Physiol. 1997;83: 623-630.

(18) Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit. 2001;7:1029-1033.

(19) Kim J, Wang Z, Heymsfield SB, et al. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr. 2002;76: 378-383.

(20) Studenski SA, Lai SM, Duncan PW, Rigler SK. The impact of self-reported cumulative comorbidity on stroke recovery. Age Ageing. 2004;33:195-198.

(21) Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. San Antonio, Tex: The Psychological Corporation, Harcourt Brace Jovanovich; 1981.

(22) Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res. 1985;5:24-37.

(23) Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-M94.

(24) Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749.

(25) Kuo HK, Leveille SG, Yen CJ, et al. Exploring how peak leg power and usual gait speed are linked to late-life disability: data from the National Health and Nutrition Examination Survey (NHANES), 1999-2002. Am J Phys Med Rehabil. 2006;85:650-658.

(26) Forrest KY, Zmuda JM, Cauley JA. Correlates of decline in lower extremity performance in older women: A 10 year follow-up study. J Gerontol A Biol Sci Med Sci. 2006;61:1194-1200.

(27) Sternfeld B, Ngo L, Satariano WA, Tager IB. Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am J Epidemiol. 2002;156: 110-121.

(28) Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36: 1134-1141.

(29) Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56:779-786.

(30) Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87:599-603.

(31) Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998;83:1886-1892.

(32) Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:80-88.

(33) Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56: M266-M272.

(34) Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002;87:5649-5657.

(35) Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653-1659.

(36) Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045-2052.

(37) Lord SR, Lloyd DG, Nirui M, et al. The effect of exercise on gait patterns in older women: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 1996; 51:M64-M70.

(38) O'Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39:1385-1394.

(39) Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003;89:971-976.

* Holtain Ltd, Crosswell, Crymych, Dyfed, United Kingdom SA41 3UF.

([dagger]) Hologic Inc, 35 Crosby Dr, Bedford, MA 01730.

([double dagger]) Nichols Institute, 1311 Calle Batido, San Juan Capistrano, CA 92673.

([section]) SAS Institute Inc, PO Box 8000, Cary, NC 27511.

CA Clay, MD, is Co-Investigator, Akron Children's Hospital, Akron, Ohio.

S Perera, PhD, is Statistician, Department of Medicine, University of Pittsburgh, Pittsburgh, Pa.

JM Wagner, PA-C, is Study Coordinator, Department of Medicine, University of Pittsburgh.

ME Miller, BS, is Study Coordinator, Department of Medicine, University of Pittsburgh.

JB Nelson, MD, is Co-Investigator, Department of Urology, University of Pittsburgh.

SL Greenspan, MD, is Principal Investigator and Professor, Department of Medicine, University of Pittsburgh, 3471 Fifth Ave, Suite 1110, Pittsburgh, PA 1521 3-3221 (USA). Address all correspondence to Dr Greenspan at: greenspans@ dom.pitt.edu.

[Clay CA, Perera S, Wagner JM, et al. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther. 2007;87:1325-1333.]

Table 1.
Participant Characteristics (a)

Parameters          No ADT               Short-Term
                    Group                ADT Group
                    (n=25) (b) (A)       (n=13) (b) (B)

Age, y ++           65.2[+ or -]5.7      74.4[+ or -]6.1
  (P<.0001)         (62.9-67.6)          (70.3-78.0)
Duration of ADT,                         3.7[+ or -]1.3
  mo                                     (2.9-4.5)
Body mass index     28.0[+ or -]3.7      28.3[+ or -]5.6
  (kg/[m.sup.2])    (26.5-29.6)          (25.0-31.7)
Body fat (%) ++     25.93[+ or -]6.1     26.2[+ or -]4.3
  (P=.0003)         (23.3-28.5)          (23.5-29.0)
Lean body mass      71.1[+ or -]5.8      71.1[+ or -]4.3
  (%) ++            (68.7-73.6)          (68.4-73.8)
  (P=.0003)
Testosterone        405.2[+ or -]129.1   20.7[+ or -]9.9
  (ng/dL) ++        (351.9-458.4)        (14.7-26.7)
  (P<0001)
Free testosterone   67.5[+ or -]24.0     2.8[+ or -]1.5
  (pg/mL) ++        (57.6-77.5)          (1.9-3.7)
  (P<.0001)
PSA + (P=.0262)     1.2[+ or -]1.4       2.2[+ or -]3.6
                    (0.6-1.7)            (0.0-4.3)
CMDI ++             32.9[+ or -]1.6      32.9[+ or -]1.1
  (P=.0010)         (32.3-33.6)          (32.3-33.6)
  Cardiovascular    6 (24.0)             1 (7.7)
  Pulmonary         3 (12.0)             2 (15.4)
  Musculoskeletal   18 (72.0)            9 (69.2)
  Diabetes          0 (0.0)              0 (0.0)
  Vision            4 (16.0)             4 (30.8)
  General           3 (12.0)             2 (15.4)
    symptoms
  Neurologic        5 (20.0)             4 (30.8)

Parameters          Long-Term           Control
                    ADT Group           Group
                    (n=42) (b) (C)      (n=20) (b) (D)

Age, y ++           73.1[+ or -]6.8     68.7[+ or -]7.1
  (P<.0001)         (71.0-75.2)         (65.4-72.0)
Duration of ADT,    30.7[+ or -]28.9
  mo                (21.7-39.7)
Body mass index     28.1[+ or -]4.2     27.6[+ or -]2.7
  (kg/[m.sup.2])    (26.8-29.4)         (26.3-28.9)
Body fat (%) ++     30.5[+ or -]5.2     25.6[+ or -]2.8
  (P=.0003)         (28.8-32.1)         (24.3-26.9)
Lean body mass      66.7[+ or -]4.9     71.2[+ or -]2.8
  (%) ++            (65.2-68.2)         (69.9-72.5)
  (P=.0003)
Testosterone        46.4[+ or -]112.1   457.5[+ or -]127.9
  (ng/dL) ++        (11.4-81.3)         (397.6-517.4)
  (P<0001)
Free testosterone   8.0[+ or -]21.5     78.9[+ or -]23.5
  (pg/mL) ++        (1.2-14.8)          (67.5-90.2)
  (P<.0001)
PSA + (P=.0262)     0.6[+ or -]1.4      1.5[+ or -]1.2
                    (0.1-1.0)           (0.9-2.1)
CMDI ++             32.6[+ or -]1.7     34.4[+ or -]1.3
  (P=.0010)         (32.1-33.2)         (33.8-34.9)
  Cardiovascular    10 (23.8)           1 (5.0)
  Pulmonary         7 (16.7)            3 (15.0)
  Musculoskeletal   31 (73.8)           10 (50.0)
  Diabetes          3 (7.1)             0 (0.0)
  Vision            12 (28.6)           8 (40.0)
  General           6 (14.3)            0 (0.0)
    symptoms
  Neurologic        12 (28.6)           6 (30.0)

Parameters          Pair-wise Differences (95% Confidence Interval)

                    A vs B           A vs C           A vs D

Age, y ++           -9.2 **          -7.9 **          -3.5
  (P<.0001)         (-13.6, -4.8)    (-11.1, -4.6)    (-7.3, 0.4)
Duration of ADT,
  mo
Body mass index     -0.3             -0.1             0.4
  (kg/[m.sup.2])    (-3.0, 2.5)      (-2.1, 2.0)      (-2.0, 2.9)
Body fat (%) ++     -0.3             -4.6 **          0.3
  (P=.0003)         (-3.0, 3.2)      (-7.1, -2.0)     (-2.7, 3.3)
Lean body mass      0.0              4.4 **           0.0
  (%) ++            (-3.3, 3.4)      (2.0, 6.9)       (-2.9, 2.8)
  (P=.0003)
Testosterone        384.5 **         358.8 **         -52.3
  (ng/dL) ++        (307.1, 461.2)   (302.1, 415.5)   (-119.7, 15.0)
  (P<0001)
Free testosterone   64.8 **          59.5 **          -11.3
  (pg/mL) ++        (50.4, 79.2)     (48.8, 70.2)     (-24.1, 1.5)
  (P<.0001)
PSA + (P=.0262)     -1.0             0.6              -0.4
                    (-2.2, 0.2)      (-0.3, 1.5)      (-1.4, 0.7)
CMDI ++             0.0              0.3              -1.4 **
  (P=.0010)         (-1.0, 1.0)      (-0.5, 1.0)      (-2.3, -0.5)
  Cardiovascular
  Pulmonary
  Musculoskeletal
  Diabetes
  Vision
  General
    symptoms
  Neurologic

Parameters          Pair-wise Differences (95% Confidence Interval)

                    B vs C          B vs D             C vs D

Age, y ++           1.3             5.7 *              4.4 *
  (P<.0001)         (-2.8, 5.4)     (1.11, 10.3)       (0.9, 7.9)
Duration of ADT,
  mo
Body mass index     0.2             0.7                0.5
  (kg/[m.sup.2])    (-2.3, 2.8)     (-2.2, 3.6)        (-1.7, 2.7)
Body fat (%) ++     -4.3 *          0.6                4.9 **
  (P=.0003)         (-7.5, -1.0)    (-3.0, 4.2)        (2.2, 7.5)
Lean body mass      4.4 **          0.0                -4.5 **
  (%) ++            (1.3, 7.5)      (-3.5, 3.4)        (-7.0, 1.9)
  (P=.0003)
Testosterone        -25.7           -436.8 **          -411.1 **
  (ng/dL) ++        (-96.9, 45.5)   (-516.8, -356.8)   (-472.1, -350.1)
  (P<0001)
Free testosterone   -5.2            -76.1 **           -70.8 **
  (pg/mL) ++        (-18.6, 8.2)    (-91.2, -60.9)     (-82.5, -59.2)
  (P<.0001)
PSA + (P=.0262)     1.6 **          0.7                -0.9
                    (0.6, 1.9)      (-0.6, 1.9)        (-1.9, 0.0)
CMDI ++             0.3             -1.4 *             -1.7 **
  (P=.0010)         (-0.7, 1.2)     (-2.5, -0.3)       (-2.5, -0.9)
  Cardiovascular
  Pulmonary
  Musculoskeletal
  Diabetes
  Vision
  General
    symptoms
  Neurologic

(a) ADT=androgen deprivation therapy, PSA=prostate-specific antigen,
CMDI=Comorbidity Disease Index. For overall 4-group comparisons:
+ = P < .05, ++ = P <.01 . For pair-wise comparisons:

(b) Data are mean[+ or -]SD (range), CMDI data are n (%).

Table 2.
Functional and Visuomotor Performance (a)

Parameters               No ADT             Short-Term
                         Group,             ADT
                         Mean[+ or -]SD     Group,
                         (95% CI)           Mean[+ or -]SD
                         (A)                (95% CI)
                                            (B)
DSST + (P=.0148)         42.9[+ or -]10.0   44.2[+ or -]13.8
                         (38.7-47.0)        (35.8-52.5)
9-Hole Peg Test time:    24.8[+ or -]4.4    25.0[+ or -]4.5
  dominant hand (s)      (23.0-26.6)        (22.4-27.7)
9-Hole Peg Test time:    25.9[+ or -]4.5    26.8[+ or -]4.5
  nondominant hand (s)   (24.0-27.7)        (24.0-29.5)
4-m gait speed           1.06[+ or -]0.13   1.04[+ or -]0.25
  (m/s) + (P=.0388)      (1.01-1.12)        (0.89-1.20)
Chair rise time (s)      13.7[+ or -]2.7    13.2[+ or -]2.8
                         (12.6-14.9)        (11.5-15.0)
SPPB + (P=.0177)         10.4[+ or -]0.9    10.4[+ or -]1.7
                         (10.1-10.8)        (9.4-11.4)

Parameters               Long-Term          Control
                         ADT                Group,
                         Group,             Mean[+ or -]SD
                         Mean[+ or -]SD     (95% CI)
                         (95% CI)           (D)
                         (C)
DSST + (P=.0148)         42.7[+ or -]9.8    47.6[+ or -]12.5
                         (39.7-45.8)        (41.7-53.5)
9-Hole Peg Test time:    24.7[+ or -]4.6    25.3[+ or -]4.6
  dominant hand (s)      (23.2-26.1)        (23.2-27.5)
9-Hole Peg Test time:    27.2[+ or -]8.5    25.0[+ or -]3.2
  nondominant hand (s)   (24.5-29.8)        (23.5-26.5)
4-m gait speed           0.99[+ or -]0.21   1.17[+ or -]0.26
  (m/s) + (P=.0388)      (0.93-1.06)        (1.04-1.29)
Chair rise time (s)      15.2[+ or -]3.8    14.5[+ or -]2.5
                         (14.0-16.4)        (13.3-15.6)
SPPB + (P=.0177)         9.6[+ or -]1.7     10.3[+ or -]0.9
                         (9.1-10.1)         (9.9-10.7)

Parameters               Adjusted Differences (b) (95% CI)

                         A vs B          A vs C          A vs D

DSST + (P=.0148)         -5.1            -3.1            -2.9
                         (-12.9, 2.8)    (-9.3, 3.1)     (-9.6, 3.8)
9-Hole Peg Test time:    0.2             1.1             -0.4
  dominant hand (s)      (-3.3, 3.7)     (-1.7, 3.8)     (-3.4, 2.6)
9-Hole Peg Test time:    -0.2            -0.7            0.1
  nondominant hand (s)   (-5.0, 4.6)     (-4.5, 3.0)     (-4.0, 4.1)
4-m gait speed           -0.1            0.1             -0.1
  (m/s) + (P=.0388)      (-0.22, 0.10)   (-0.07, 0.18)   (0.26, 0.01)
Chair rise time (s)      0.2             -1.4            -1.5
                         (-2.2, 2.6)     (-3.3, 0.5)     (-3.5, 0.6)
SPPB + (P=.0177)         -0.3            0.8 *           0.4
                         (1.2, 0.7)      (0.1, 1.6)      (-0.4, 1.2)

Parameters               Adjusted Differences (b) (95% CI)

                         B VS C          B vs D          C vs D

DSST + (P=.0148)         2.0             2.2             0.2
                         (-5.0, 9.0)     (-5.7, 10.1)    (-6.3, 6.7)
9-Hole Peg Test time:    0.9             -0.6            -1.4
  dominant hand (s)      (-2.3, 4.0)     (-4.1, 2.9)     (-4.3, 1.4)
9-Hole Peg Test time:    -0.5            0.2             0.8
  nondominant hand (s)   (-4.8, 3.7)     (-4.5, 5.0)     (-3.1, 4.7)
4-m gait speed           0.1             -0.1            -0.18 **
  (m/s) + (P=.0388)      (-0.02, 0.26)   (-0.22, 0.10)   (-0.31, -0.05)
Chair rise time (s)      -1.5            -1.6            -0.1
                         (-3.7, 0.6)     (-4.1, 0.8)     (-2.1, 1.9)
SPPB + (P=.0177)         1.1 *           0.7             -0.4
                         (0.2, 1.9)      (-0.3, 1.7)     (1.2, 0.4)

(a) ADT=androgen deprivation therapy, DSST=Digit Symbol Substitution
Test, SPPB=Short Physical Performance Battery, CI=confidence interval.
For overall 4-group comparisons adjusted for covariates age,
Comorbidity Disease index, and percentage of body fat: + = P < .05.
For pair-wise comparisons adjusted for covariates age, Comorbidity
Disease Index, and percentage of body fat: * = P<.05, ** = p < .01.

(b) Adjusted for age, Comorbidity Disease Index, body mass index,
and percentage of body fat.

Table 3.
Pearson Correlations (a)

Parameters            DSST       9-Hole      9-Hole Peg    Walk
                                 Peg Test:   Test:         Speed
                                 Dominant    Nondominant   (m/s)
                                 Hand (s)    Hand (s)

Age, y                -.174       .083        .173         -.228 *
CMDI                   .361 **   -.015       -.225 *        .119
Body mass index,      -.117      -.010       -.061          .048
  kg/[m.sup.2]
Body fat, %           -.107       .050       -.004          .007
Lean body mass, %      .080      -.041        .000         -.004
Testosterone, ng/dL    .054       .037       -.127          .145
Free tetosterone       .094       .056       -.136          .140
  pg/mL

Parameters            Chair      SPPB
                      Rise (s)

Age, y                 .025      -.108
CMDI                  -.197 *     .264 **
Body mass index,       .045      -.018
  kg/[m.sup.2]
Body fat, %            .193      -.134
Lean body mass, %     -.193       .136
Testosterone, ng/dL   -.096       .187
Free tetosterone      -.092       .188
  pg/mL

(a) DSST=Digit Symbol Substitution Test, SPPB=Short Physical
Performance Battery, CMDI=Comorbidity Disease Index. * = p <.05,
** = P < .01.